dissemination
[대역어] 파종
[용어속성] Term
[용어속성] Term
What triggers online help-seeking retransmission during the COVID-19 period? Empirical evidence from Chinese social media
Research Article
[키워드] Analysis
approach
Characteristics
Chinese
Completeness
conducted
COVID-19
diffusion
disease severity
dissemination
distribution
driving
effective
empirical evidence
information
instrumental support
Limited
media
medical resource
nine
Probability
promote
provide
public health emergency
Quantitative
Research
reveal
seeking
severity
Support
Trigger
[DOI] 10.1371/journal.pone.0241465 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0241465 PMC 바로가기 [Article Type] Research Article
Salivary and Nasal Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid): A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] β-cyclodextrin
1:1
absence
anticipated
Antiviral
antivirals
Arm
blinded
Breastfeeding
center
change
citrox®
clinic
clinical
Clinical sign
clinical trial
Complete
composed
conducted
Control
control group
COVID-19
criteria
detection
Diagnosis
dissemination
element
eligibility
Endocarditis
Evolution
France
French
hospital
include
Infection
Infirmary
Intervention
investigator
laboratory technician
lack
less
Mouthwash
mouthwashe
nasal
Nasal sample
number
Nurse
objective
outcome
Parallel Arm
participant
Participants
Patient
PCR assay
performed
Placebo
protocol
question
random
randomisation
randomised
randomised controlled trial
RCT
Registered
reported
risk
Roux
salivary
salivary and real-time PCR
Sample size
SARS-CoV 2
SARS-CoV-2
SARS-CoV-2 viral load
SARS-CoV-2 virus
secondary
Standard
status
study groups
Study protocol
supplementary material
the SARS-CoV-2
Trial
understanding
Viral load
website
[DOI] 10.1186/s13063-020-04846-6 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04846-6 PMC 바로가기 [Article Type] Letter
The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future
Review article
[키워드] acquisition
acute respiratory syndrome
benefit
Biomedical research
Cancer
cancers
Care
change
changed
changes in
circulation
clinical
clinics
Complication
Comprehensive
conducted
Context
coronavirus disease
Coronavirus-2
COVID-19
COVID-19 pandemic
creating
demographic characteristics
dissemination
Effect
Efficiency
ENhance
Future
genitourinary
Health
Health services accessibility
highest
Impact
IMPROVE
increasingly
initial
Interaction
interactions
Intervention
investigation
less
maintain
mental health
objective
offer
pandemic
Patient
Patient care
pattern
physician
provided
Radiotherapy
raise
reduced
Research
risk
SARS-CoV-2
solution
Telemedicine
threshold
Treatment
Trial
Virtual care
[DOI] 10.1016/j.eururo.2020.08.030 [Article Type] Review article
[DOI] 10.1016/j.eururo.2020.08.030 [Article Type] Review article
PTSD treatment in times of COVID-19: A systematic review of the effects of online EMDR
Short communication
[키워드] Affect
Care
Cognitive behavioural therapy
COVID-19
desensitization
dissemination
Effect
Emdr
eye
Internet
measure
mental health
movement
open trial
Patient
performed
professional
PTSD
systematic review
Treatment
Trial
[DOI] 10.1016/j.psychres.2020.113438 [Article Type] Short communication
[DOI] 10.1016/j.psychres.2020.113438 [Article Type] Short communication
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
accompany
adjusted
Admission
Affair
age
analyst
antibiotic
antiviral therapy
Arrhythmias
blinded
Breastfeeding
breathing ambient air
Care
Child-Pugh score
Chronic kidney disease
city
classical
clinical
clinical effectiveness
Clinical improvement
clinical sample
clinical symptom
clinically
Coma
Combination
Comorbidity
comparator
Compliance
conducted
control arm
control group
Controlled clinical trial
COVID-19
current
Dammam
data entry
death
deficiency
defined
diagnosed with COVID-19
dialysis
discharge
discharged
disease
disease onset
dissemination
drug
ECMO
effective sample size
Efficacy
Efficacy and safety
eight
element
enrolled
Enrollment
evaluate
Evidence
experimental arm
extracorporeal membrane oxygenation
Faisal
Favipiravir
female
G6PD
Glucose-6-phosphate
hereditary xanthinuria
HIV
hospital
Hospital admission
Hospitalized
Hydroxychloroquine
Hyperuricemia
ICU admission
Imam
immunosuppressive
in vitro
include
information
Intervention
intravenous fluid
invasive ventilation
investigator
Jeddah
King
less
limit
Liver damage
Major
malignancy
medication
moderate
multicenter
Multicenter trial
Myocardial infarction
noninvasive
nonpregnant
number
objective
ongoing trial
outcome
oxygen saturation
Palliative care
participant
Patient
PCR
pregnant
primary endpoint
prior diagnosis
prognostic
prolonged QT interval
protocol
QT interval
randomised
randomised controlled trial
randomization
Randomized
receiving
recruitment
reference
risk
Sample size
SARS-CoV-2
Saudi Arabia
selected
seven-category ordinal scale
Standard
Stratification
study drug
Study protocol
subject
supplemental oxygen
Supportive treatment
Symptom
System
tablets
the patient
therapeutic agent
therapy
transferred
Treatment
Trial
ULN
Urinary tract
use of hydroxychloroquine
vasopressor support
ventricular
viral infection
Web
website
with COVID-19
xanthine
[DOI] 10.1186/s13063-020-04825-x PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04825-x PMC 바로가기 [Article Type] Letter
Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] adjuvant
Administered
Adverse
age
alanine aminotransferase
All study participant
allergy
approved
ARDS
Aspartate transaminase
Aspirin
atorvastatin
benefit
bleeding
block randomization
Breastfeeding
C-reactive protein
characterized
clinical
Clinical deterioration
Clinical improvement
Clinical outcome
Coagulopathy
collected data
computer-generated
conducted
confirmed case
control group
COVID-19
COVID-19 patient
COVID-19 patients
CPK
creatine phosphokinase
Critical
derivative
discharge
dissemination
dose
drug
drug interaction
ECMO
Effect
element
Endotracheal intubation
enrolment
ethical committee
evaluated
examined
excluded
exclusion criteria
Final
Hepatitis
HIV
Hospital admission
hospital discharge
hospitalisation
ICMR
ICU admission
in-hospital mortality
include
Inclusion
India
infected with SARS-CoV-2
Inflammatory marker
interim analysis
liver
management
mechanical ventilation
Medical Science
medication
Mortality
myalgia
National Cancer Institute
New
Non-invasive
number
objective
Open-label
Other
outbreak
outcome
outcomes
pandemic
parallel-group
participant
Patient
patients
Platelet
Pregnancy
Primary outcome
progression
Protease inhibitor
protease inhibitors
protocol
randomised
Randomised control trial
randomised controlled trial
randomize
Randomized
receiving
recruited
recruitment
reference
Registered
registry
renal replacement therapy
respiratory
RT-PCR
Sample size
SARS-CoV-2
SARS-COV-2 infection
secondary outcome
serum
Shock
statin
status
study period
Study protocol
supplementary material
symptom onset
Tablet
therapy
Treatment protocol
Trial
troponin
usual care
website
WHO
written consent
written Informed Consent
[DOI] 10.1186/s13063-020-04840-y PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04840-y PMC 바로가기 [Article Type] Letter
A Founder Effect Led Early SARS-CoV-2 Transmission in Spain
스페인에서 초기 SARS-CoV-2 전파를 주도한 파운더 효과
Genetic Diversity and Evolution
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
analyses
Analysis
Bayesian
characterized
clade
clades
Cluster
coronavirus
country
COVID-19
COVID-19 case
D614 variant
D614G
D614G substitution
diffusion
displaying
dissemination
Effect
Europe
European country
explosion
FIVE
founder effect
higher infectivity
independent
majority
maximum-likelihood
MOST
Multiple
occurred
ORF8
pandemic
phylodynamic
phylodynamics
Phylogenetic
phylogenetic analyses
phylogeography
Prevalence
prevalent
pseudotyped virion
pseudotyped virions
Region
replaced
REPLACED BY
respiratory
S gene
SARS-CoV-2
SARS-CoV-2 pandemic
SARS-CoV-2 spike protein
sequence
sequences
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
Spain
Spike protein
the epidemic
the SARS-CoV-2
the spike protein
transmitted
variant
virus
viruses
whole-genome
Whole-genome sequence
Wuhan
Wuhan, China
[DOI] 10.1128/JVI.01583-20 PMC 바로가기 [Article Type] Genetic Diversity and Evolution
[DOI] 10.1128/JVI.01583-20 PMC 바로가기 [Article Type] Genetic Diversity and Evolution
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
24 hour
Ability
absence
accompany
activity
Administered
administration
Admission
adverse events
Affect
age
alkaline phosphatase
allergy
ALT
alternative hypothesis
ambient
Analysis
ANC
Anti-inflammatory
anticipated
antipyretics
antivirals
Arm
ARMS
assumed
AST
Baltimore
baseline
benefit
blinded
block
block randomization
Blood
breastfeeding women
Bronchoalveolar lavage
calculated
Care
Cellulose
center
Chest
chest X-ray
childbearing potential
clinical
clinical condition
Clinical course
clinical impact
Clinical improvement
Clinical outcome
clinical status
clinical trial
collected
competing
Compliance
concealed
Concentration
Concomitant
conditions
conducted
congestive heart failure
Contraception
Control
control arm
Conventional
Corticosteroids
COVID-19
COVID-19 disease
COVID-19 infection
COVID-19 pandemic
criteria
criterion
Critical
CT scan
current
Day
Declaration of Helsinki
decrease
defined
detect
direct bilirubin
disease
disorder
dissemination
dose
double-blind
drug
Drug administration
drug-drug interaction
drugs
Duration
ECMO
Efficacy
Efficacy and safety
element
eligible
endosomal pH
Enrollment
ethnic group
evaluate
Evidence
exclusion
expected
exploratory endpoint
extracorporeal membrane oxygenation
Face mask
FDA
Fisher
Good
group
handling
harmonization
hematologic
histocompatibility complex
Hospitalization
Hospitalized
hospitalized patient
Hydroxychloroquine
Hypothesis
ICU
IL-6 levels
Imatinib
immunomodulatory
immunomodulatory drugs
IND
information
Informed consent
inhibitory activity
intensive care
intensive care unit
intention to treat
interfere
International Conference
invasive
Invasive mechanical ventilation
investigational agent
investigator
ITT
Laboratory
Last
limit
limitation
liver
Local
lysosomal sequestration
magnitude
matching placebo
mechanical ventilation
men and women
MHC
mononuclear cell
Mortality
nasal
nasopharyngeal
Nasopharyngeal swab
neutrophil count
New
new oxygen use
non-invasive ventilation
non-rebreather mask
not blinded
null hypothesis
number
objective
off-label
off-label use
Oropharyngeal
outcome
outcomes
oxygen
Oxygenation
P450
packaged
PaO
participant
Participants
Patient
patients
patients with ARDS
patients with COVID-19
PBMCs
performed
Pharmacist
Pharmacy
phase 3 study
Placebo
placebo-controlled
Pneumonia
positive COVID-19
Practice
primary analysis
primary endpoint
principal
progression
proportion
protocol
Psychiatric
Radiographic
random number generator
randomised controlled trial
randomization
Randomized
Randomized controlled trial
receive
receiving
recruitment
Regulatory
renal dysfunction
renal replacement therapy
replication of SARS-CoV-2
required
requiring supplemental oxygen
Respiratory illness
respiratory tract
risk
RT-PCR
Safety
Sample size
sarilumab
SARS-CoV
SARS-CoV-2
secondary endpoint
Seizure
Serious Adverse Events
service
severe disease
severity
significance level
Site
Society
stability
Standard of care
status
stratified
study drug
study enrollment
study outcomes
Study protocol
subject
submitted
supplemental oxygen
Support
Suspension
symptomatic
Tablet
temperature
Test
the patient
the primary endpoint
time
TKI
TKI-induced attenuation of vascular leak
TKI-induced prevention and treatment lung inflammation
Tocilizumab
transcriptomics
Treatment
treatment allocation
treatment arm
treatments for COVID-19
Trial
two-sided
tyrosine kinase inhibitor
uncontrolled
university
unstable angina
vasopressors
ventilator
ventilator free days
viral ABL-1 signalling
website
with COVID-19
[DOI] 10.1186/s13063-020-04819-9 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04819-9 PMC 바로가기 [Article Type] Letter
Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
Letter
[키워드] 1:1
Adverse drug reaction
allergy
allocation sequence
antibody tests
anticipated
Arm
ARMS
assigned
Bandar Abbas
Blinding
block randomization
Breastfeeding
carried
China
cirrhosis
clinical
Clinical improvement
company
Computed tomography
conditions
Confirmed
Control
control group
Controlled trial
COVID-19
criteria
Critical
Department
Diagnosis
dissemination
dose
Efficacy and safety
element
evaluate
Favipiravir
Fever
FIVE
generate
Hepatitis
history
Hospital stay
Hospitalization
ill patient
in both groups
incidence
India
infection with SARS-CoV-2
interferon
intervention group
Iran
liver diseases
Lopinavir/ritonavir
nasopharyngeal sample
number
objective
Open-label
Other
outcome
parallel-group
participant
Patient
patients
Phase 3
Placebo
Pneumonia
polymerase chain
Primary outcome
protocol
random
randomization
Randomized
Randomized controlled trial
receive
registry
renal
respiratory
routine care
RT-PCR
Sample size
SARS-CoV-2
screened
secondary outcome
single-center
Study protocol
treatment arm
Trial
trial protocol
two group
Viral load
web-based system
website
X-ray
Zhejiang
[DOI] 10.1186/s13063-020-04747-8 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04747-8 PMC 바로가기 [Article Type] Letter